# A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease

> **NCT03782376** · PHASE3 · COMPLETED · sponsor: **Janssen-Cilag Ltd.** · enrollment: 215 (actual)

## Conditions studied

- Crohn Disease

## Interventions

- **DRUG:** Ustekinumab approximately 6 mg/kg (IV)
- **DRUG:** Placebo (SC)
- **DRUG:** Placebo (IV)
- **DRUG:** Ustekinumab 90 mg (SC) Group 1
- **DRUG:** Ustekinumab 90 mg (SC) Group 2

## Key facts

- **NCT ID:** NCT03782376
- **Lead sponsor:** Janssen-Cilag Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-20
- **Primary completion:** 2022-08-19
- **Final completion:** 2023-01-10
- **Target enrollment:** 215 (ACTUAL)
- **Last updated:** 2025-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03782376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03782376, "A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03782376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*